Arbutus Biopharma Corp Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q3 2017 to Q3 2023
-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
-
Summary
-
Arbutus Biopharma Corp quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q3 2017 to Q3 2023.
- Arbutus Biopharma Corp Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending September 30, 2023 was -$20.1M, a 14.4% decline year-over-year.
- Arbutus Biopharma Corp annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$63.7M, a 61.7% increase from 2019.
- Arbutus Biopharma Corp annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2019 was -$166M, a 171% decline from 2018.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)